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Telomeres provide stability to eukaryotic chromosomes and consist
of tandem DNA repeat sequences. Telomeric repeats are synthe-
sized and maintained by a specialized reverse transcriptase, termed
telomerase. Tetrahymena thermophila telomerase contains two
essential components: Tetrahymena telomerase reverse transcrip-
tase (tTERT), the catalytic protein component, and telomerase RNA
that provides the template for telomere repeat synthesis. In addi-
tion to these two components, two proteins, p80 and p95, were
previously found to copurify with telomerase activity and to
interact with tTERT and telomerase RNA. To investigate the role of
p80 and p95 in the telomerase enzyme, we tested the interaction
of p80, p95, and tTERT in several different recombinant expression
systems and in Tetrahymena extracts. Immunoprecipitation of
recombinant proteins showed that although p80 and p95 associ-
ated with each other, they did not associate with tTERT. In in vitro
transcription and translation lysates, tTERT was associated with
telomerase activity, but p80 and p95 were not. p80 bound telom-
erase RNA as well as several other unrelated RNAs, suggesting p80
has a general affinity for RNA. Immunoprecipitations from Tetra-
hymena extracts also showed no evidence for an interaction
between the core tTERTytelomerase RNA complex and the p80 and
p95 proteins. These data suggest that p80 and p95 are not asso-
ciated with the bulk of active telomerase in Tetrahymena.
Telomeres provide stability to chromosomes by preventingend degradation and end-to-end chromosome fusions (re-
viewed in refs. 1 and 2). Telomeric DNA consists of repetitive
GT-rich sequences that are conserved in most eukaryotic or-
ganisms. These DNA repeats are synthesized and maintained by
the specialized reverse transcriptase telomerase (reviewed in ref.
3). Telomerase enzyme activity was first identified in the ciliate
Tetrahymena thermophila (4). The enzyme was later found to
contain an essential RNA component that provides the template
for telomere repeat synthesis (5). Telomerase RNA components
have now been identified from many other organisms including
ciliates, yeasts, and vertebrates (6–15). The catalytic protein
component, termed telomerase reverse transcriptase (TERT),
was first discovered in the ciliate Euplotes audiculatus (16).
Homologues have been found in yeast, mammals, plants, ciliates,
and Caenorhabditis elegans (17–27). Both human and Tetrahy-
mena telomerase enzyme activity can be reconstituted in an in
vitro transcription and translation reaction in rabbit reticulocyte
lysates expressing TERT in the presence of telomerase RNA (25,
28, 29). Human telomerase activity also has been reconstituted
in yeast by coexpressing human TERT (hTERT) and human
telomerase RNA and by the addition of human telomerase RNA
to recombinant hTERT expressed in insect cells (30, 31). Thus,
these two components are the minimal core components of the
telomerase enzyme.
In addition to the core telomerase components, several other
proteins have been found to be associated with telomerase. In
yeast, EST1 and EST3 interact with telomerase in vivo and in
vitro (32, 33). Deletion of each of these genes or the genes
encoding TERT or telomerase RNA results in the identical
telomere shortening phenotype, indicating EST1 and EST3 are
essential for telomerase action in vivo (32). However, telomerase
activity is still present in cells that lack these genes (34). EST1
and EST3 physically interact with telomerase and telomerase
RNA, indicating they are telomerase-associated proteins (33). In
human cells, telomerase-associated protein 1 (TEP1) and the
chaperone proteins hsp90 and p23 were found to interact with
the hTERT protein and telomerase activity (35, 36). The pro-
teins L22, hStau, and dyskerin bind human telomerase RNA and
are associated with telomerase activity in cell extracts (37, 38).
In the ciliate E. audiculatus, the protein p43 was identified by
copurification with TERT and telomerase activity (39). p43 is
physically associated with telomerase activity in cell extracts and
is a homologue of the human La protein (40).
In Tetrahymena, p80 and p95 were identified by copurification
with telomerase enzyme activity and telomerase RNA (41).
These two proteins tightly interact with each other and were
reported to bind to telomerase RNA and Tetrahymena TERT
(tTERT) in Tetrahymena extracts (25). Purified recombinant p80
and p95 proteins were shown to bind to in vitro-transcribed
telomerase RNA, and p95 bound to telomeric oligonucleotides,
suggesting these proteins are integral components of telomerase
(42). However, deletion of these proteins in Tetrahymena did not
affect the levels of telomerase RNA or telomerase activity (43).
A mammalian telomerase protein, TEP1, was identified by
homology to the p80 protein from Tetrahymena (35, 44). TEP1
was shown to associate with telomerase activity, telomerase
RNA, and hTERT in human cell extracts. TEP1 has an amino-
terminal region of homology to p80 and a large carboxyl-
terminal domain with 12 WD repeat motifs (35). In addition to
its association with telomerase, TEP1 is a component of the
cytoplasmic particles termed vaults. Vaults are ribonucleopro-
tein (RNP) complexes that contain a small RNA, which binds to
TEP1 (45). The role of TEP1 for telomerase function is not clear,
as the absence of TEP1 does not effect telomerase activity or
telomere length in mice (46).
To understand the role of telomerase-associated proteins, we set
out to characterize the interaction of p80 and p95 with Tetrahymena
telomerase. Our analysis of recombinant proteins suggests that p80
and p95 form a complex with each other but do not associate with
the catalytic component tTERT in vitro. We further show that in
Tetrahymena extracts there is no measurable interaction of these
proteins with telomerase, suggesting that they are not associated
with the bulk of active telomerase.
Materials and Methods
Gene Construction. The Tetrahymena genetic code differs from
other eukaryotes (47). To express p80 and p95, the synthetic
genes were redesigned to convert the UAG and UAA (stop)
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codons that encode glutamine in Tetrahymena to the appropriate
CAG codon. Overlapping oligonucleotides of ’100 bases were
synthesized (Bioserve Biotechnologies, Laurel, MD). These
oligonucleotides were designed with convenient restriction en-
zyme sites for subsequent cloning. Overlapping oligonucleotides
were annealed and extended by PCR to create a series of
overlapping DNA fragments. These overlapping fragments were
annealed and extended further by PCR to create 800–1,000
base-pair fragments. The fragments were then cloned into
pBluescript (Stratagene) and pSE280 (Invitrogen) vectors for
p80 and p95, respectively. Any point mutations or small deletions
were corrected by site-directed mutagenesis (CLONTECH).
The tTERT gene was generated by a similar procedure and was
a kind gift from Kathleen Collins, University of California,
Berkeley (25).
Escherichia coli Protein Expression and Purification. p80 was tagged
at the amino terminus with six histidines (6His) and was ex-
pressed from the plasmid pQE30 (Qiagen, Chatsworth, CA) in
TG1 bacteria. p95 and tTERT were also tagged with six histi-
dines at their amino termini and expressed from the plasmid
pBADyHisA in LMG194 bacterial strain (Invitrogen). To ex-
press p80 and p95 as untagged recombinant proteins, the genes
were cloned into pBADyHisA followed by the removal of the
6His tag sequence. Colonies were initially grown overnight in 5
ml of LB at 37°C and then inoculated into 50 ml of LB and grown
to OD 5 0.6 at 37°C. Expression was induced with 100 mM
isopropyl b-D-thiogalactoside (pQE30) or 0.02% (pBAD) arab-
inose, and cells were grown at 23°C for 2–3 h. Cells were
harvested in 50 mM NaH2PO4 (pH 8.0)y300 mM NaCly10 mM
imidazoley0.5% Triton X-100 with 10 mgyml leupeptin and 0.1
mM PMSF. Cell suspensions were incubated with 1 mgyml
lysozyme for 30 min on ice. Lysates were sonicated and centri-
fuged at 10,000 3 g for 30 min at 4°C. Purification of 6His-tagged
proteins with Ni21-NTA resin was performed as described by the
manufacturer (Qiagen). Fractions were analyzed by SDSy7.5%
PAGE and stained with Coomassie blue. Peak fractions were
concentrated with Centricon spin columns (Amicon).
Antibodies and Immunoprecipitations. The p80-R and p95-R anti-
bodies were raised against the purified 6His-tagged recombinant
proteins. p80-P and p95-P antibodies were raised against syn-
thesized peptides from the p80 sequence CRKKTMFRYLSVT-
NKQKWDQTKKKRKEN and p95 sequence CGTYYDYNS-
DRW. TERT-P antibody was raised against a peptide from the
carboxyl terminus of the protein: CNNLIQDIKTLIPKISAK-
SNQQNTN. All immunogens were conjugated to keyhole limpet
hemacyanin and injected into rabbits (Convance, Denver, PA).
The H1 antibody was raised against Tetrahymena linker histone
protein H1 and was obtained from the laboratory of David Allis,
University of Virginia, Charlottesville. For immunoprecipita-
tions from E. coli, Sf9 insect cell extracts, and rabbit reticulocyte
lysates, 1–2 ml of antisera was prebound to protein A Sepharose
beads (Amersham Pharmacia) and washed in PBS. For immu-
noprecipitation from Tetrahymena extracts, antibodies were
cross-linked to protein A beads as described in the Immunopure
protein A IgG orientation kit (Pierce). Use of cross-linked
antibody significantly reduced background during Western anal-
ysis. The antibody beads were incubated with extracts containing
1 mg of total protein at 4°C for 2 h. Beads were washed four times
with the buffer each extract was made in and resuspended in SDS
loading buffer. Elution of antigens from the cross-linked anti-
bodies was performed with 0.1 M glycine (pH 2.8). Samples
eluted at low pH were neutralized with final concentration of 30
mM Tris (pH 9.0) before resuspending in SDS loading buffer. All
antibodies have similar immunoprecipitation efficiencies of
’50% based on immunoprecipitations of proteins from rabbit
reticulocyte lysates.
Western Analysis and Autoradiography. After SDSyPAGE, pro-
teins were transferred to Immobilon-P poly(vinylidene difluo-
ride) membrane (Millipore) in 48 mM Trisy39 mM glyciney20%
methanol by using a semidry transfer apparatus at 15 V for 30
min (Bio-Rad). The membrane was blocked with 5% dry milk in
TBSy0.1% Tween 20. The primary antibodies p80-R and p95-R
were used at 1:10,000 dilution, and TERT-P antibody was used
at 1:5,000 dilution in 5% dry milk in TBSy0.1% Tween 20 and
incubated with blocked membrane. Goat anti-rabbit conjugated
to horseradish peroxidase (Bio-Rad) was used at 1:5,000 dilution
followed by enhanced chemiluminescence (Amersham Pharma-
cia). Protein gels to be detected by autoradiography were fixed
with 50% methanol and 10% acetic acid for 30 min and then
soaked in fluorographic reagent for 15 min (Amersham Phar-
macia). Gels were dried and exposed to Hyperfilm (Amersham
Pharmacia).
Baculovirus Expression. p80, p95, and tTERT were cloned into
pFastBac1 or pFastBacHT vectors, and the protocol described in
the Bac-to-Bac expression system was followed (GIBCOyBRL).
To produce protein from the recombinant viruses, ’25 ml of
high titer virus was used for infection of 2.0 3 106 Sf-9 insect cells
grown in Grace’s insect cell culture medium with 10% FBS.
After infection for 4–5 days with recombinant baculovirus, cells
were harvested and lysed with 50 mM NaH2PO4, pH 8.0y300 mM
NaCly0.5% Triton X-100y10 mg/ml leupeptiny0.1 mM PMSF.
Lysates were centrifuged at 10,000 3 g for 30 min at 4°C and then
used in immunoprecipitation reactions.
In Vitro Transcription and Translation Reactions. p80, p95, and
tTERT were expressed from pCITE-4a (Novagen) by using the
TNT quick coupled transcriptionytranslation system (Promega).
In vitro-transcribed telomerase RNA was added or was expressed
in the lysate from a PCR product containing the telomerase
RNA gene behind the T7 promoter. Both coexpression of
tTERT and telomerase RNA or telomerase RNA addition at
the beginning of the transcription and translation re-
action reconstituted the same level of telomerase activity.
Lysates were diluted 8-fold with 10 mM Hepes, pH 7.9y100 mM
potassium glutamatey1 mM MgCl2y10% glyceroly0.5 mg/ml
BSAy0.1 mg/ml yeast tRNAy1 mM DTT. Lysates were cen-
trifuged at 10,000 3 g to remove particulate matter before
immunoprecipitation.
In Vitro RNA Transcription. Telomerase RNA (5) was in vitro-
transcribed as described by the manufacturer (GIBCOyBRL) by
T7 RNA polymerase from a PCR product containing the gene
encoding the telomerase RNA behind the T7 promoter and
gel-purified on 4% PAGE. Full-length 7SL and U2 RNA DNA
templates for T7 transcription in rabbit reticulocyte lysates were
created by PCR from Tetrahymena genomic DNA. A random
RNA sequence for T7 transcription was generated from a PCR
template derived from the plasmid pUC19 (CLONTECH). All
in vitro transcripts contain three extra G residues at the 59 end.
Tetrahymena Extracts. Strains CU428 and B2086 were grown to
midlog phase, starved, and mated as described in ref. 41. Cells
were lysed with 10 mM Hepes, pH 7.9y10 mM KCly1 mM
MgCl2y10% glyceroly0.2% Nonidet P-40 and protease inhibitor
mixture (Roche Molecular Biochemicals) and centrifuged at
10,000 3 g at 4°C for 30 min.
Telomerase Assays. Telomerase assays were performed by using
3 ml of in vitro transcription and translation reaction lysate or 20
ml of beads containing immobilized protein in immunoprecipi-
tation wash buffer. Samples were added to a telomerase reaction
mix that contained 0.6 mM primer d(TTGGGG)3y250 mM
dTTPy0.85 mM dGTPy0.17 mM [a-32P]dGTP (3,000 Ciymmol)y








1.5 mM MgCl2y50 mM Tris acetate (pH 8.5)y1 mM spermi-
diney5 mM b-mercaptoethanoly60 mM potassium acetate. Sam-
ples were assayed in a final volume of 40 ml at 30°C for 60 min.
The reactions were phenolychloroform-extracted, precipitated,
and resolved on 8% (19:1) acrylamidey7 M ureay0.6 3 TBE
(Trisyboric acidyEDTA) gel. Dried gels were exposed to phos-
phorimager plates (Fuji) or x-ray film (Kodak).
Northern Analysis. RNA was extracted from immunoprecipitation
reactions by acid phenolychloroform and precipitated. RNA was
then resolved on 6% (19:1) acrylamidey7 M ureay1 3 TBE gels
and transferred to Hybond-N1 membrane (Amersham Phar-
macia) for 45 min at 1 amp by using an electroblotter. RNA was
UV-cross-linked to the membrane with a UV stratalinker (Strat-
agene) and then was subjected to hybridization in 200 mM
Na2HPO4, pH 7.2y15% formamidey7% SDSy1 mM EDTAy1%
BSA at 63°C. RNA was detected with random hexamer radio-
labeled DNA probes as described (48). The membrane was then
washed four times with 6 3 SSC and 0.1% SDS at 63°C and
exposed to phosphorimager plates (Fuji) or x-ray film (Kodak).
Results and Discussion
To examine the interactions of p80, p95, tTERT, and the
telomerase RNA, we expressed the four components as recom-
binant products and assayed their interactions by using several
different systems. To express the p80, p95, and tTERT proteins
in heterologous systems, the codons were redesigned to conform
to the standard eukaryotic genetic code (see Materials and
Methods). Antibodies were raised against both p80- and p95-
derived synthetic peptides and recombinant proteins. Antibodies
also were raised against a peptide from the carboxyl-terminal
region of tTERT (see Materials and Methods). Coimmunopre-
cipitation experiments were first carried out by using E. coli and
baculovirus systems to test protein–protein interactions in the
absence of telomerase RNA. The role of the telomerase RNA in
the complex was then tested by using in vitro transcription and
translation lysates as well as extracts from Tetrahymena cells.
p80, p95, and tTERT Interaction in E. coli Extracts. To test for
protein–protein interactions, p80 and p95 were expressed as
untagged proteins, and the tTERT was expressed as a 6His-
tagged fusion protein. Immunoprecipitations were performed
on extracts containing one of the proteins or from mixed extracts
containing all three proteins. The pellets from the immunopre-
cipitation reaction were then resolved by SDSyPAGE and
visualized with Coomassie blue (Fig. 1A). Each polyclonal
antibody specifically immunoprecipitated the protein it was
raised against. Preimmune serum did not immunoprecipitate any
of the three recombinant proteins. Both the p80 and p95
antibodies raised against recombinant protein were able to
coimmunoprecipitate a complex containing both p80 and p95,
indicating that these proteins associate with each other as
described (42). However, the tTERT antibody only immunopre-
cipitated tTERT, suggesting that there was no interaction be-
tween the p80yp95 complex and tTERT in this recombinant
system.
p80, p95, and tTERT Interactions in Insect Cell Extracts. There are
several reasons we might have failed to detect an association of
tTERT with p80 and p95 in the E. coli system. First, the proteins
might require a posttranslational modification not generated in
E. coli. Second, the proteins may need to be expressed and
translated in the same cell to allow complex formation. To
address these issues, we expressed the three proteins in Sf9 insect
cells by using the baculovirus expression system (see Materials
and Methods). All three proteins (p80, p95, and tTERT) were
expressed as 6His-tagged fusion proteins. The proteins were
either expressed alone or coexpressed by virus coinfection to
allow for the assembly of potential protein complexes within the
insect cells. Western analysis confirmed the expression of each
protein from insect cells expressing individual proteins or coex-
pressing p80, p95, and tTERT (data not shown). The immuno-
precipitation reactions were carried out with p80 and p95
antibodies that were raised against synthetic peptides rather than
those raised against recombinant proteins. The pellets from
these immunoprecipitation reactions were resolved by SDSy
PAGE, and proteins were detected by Western analysis with
antibodies against p80, p95, and tTERT (Fig. 1B). All three
antibodies were able to immunoprecipitate the corresponding
target protein. As observed earlier, the p80 antipeptide antibody
coimmunoprecipitated both p80 and p95 from the extracts made
from coinfected cells. The p95 antipeptide antibody immuno-
precipitated only p95 and not p80. Failure of this antibody to
immunoprecipitate the p80yp95 complex may result from inac-
Fig. 1. (A) In vitro interactions of recombinant p80, p95, and
tTERT in E. coli extracts. Immunoprecipitation reactions were
done from E. coli extracts that contain p80, p95, and tTERT
(lanes 2–13) or from a mixed extract containing all three
proteins (lanes 14–17). The samples were resolved by SDSy
PAGE and stained with Coomassie blue. The p80 and p95
recombinant proteins were expressed without any epitope
tags, whereas the tTERT protein had an amino-terminal 6His
tag. The extract used for each set of immunoprecipitations is
indicated at the top, and the antibodies used are indicated at
the top of each lane. PIS, preimmune serum. Molecular mass
marker was loaded in lane 1 with indicated masses in kDa to
the left. (B) In vitro interactions of recombinant p80, p95, and
tTERT in baculovirus-infected insect cells. p80, p95, and tTERT
were expressed individually or together in Sf9 insect cells by
baculovirus infection. All three proteins were expressed with
an amino-terminal 6His tag. Immunoprecipitations were per-
formed from cells that express individual components (lanes
1–3) or those that coexpressed p80, p95, and tTERT (lanes
4–6). Proteins were detected by Western analysis with anti-
bodies against all three proteins.
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cessibility of the specific epitope in the p80yp95 complex. As
shown above, polyclonal antibodies raised against the p95 re-
combinant protein did immunoprecipitate the p80yp95 complex
(Fig. 1 A). The antipeptide antibody against tTERT only immu-
noprecipitated tTERT and did not coimmunoprecipitate the
p80yp95 complex. Again, these immunoprecipitations failed to
show an interaction of p80yp95 with tTERT. The tTERT peptide
antibody used in these immunoprecipitation experiments may
have not detected a potential complex if its specific epitopes were
masked. To test this, we used the 6His tag placed at the amino
terminus of each protein to purify potential complexes in both
the E. coli and baculovirus expression systems. Again, no inter-
action between p80yp95 and tTERT was seen when each protein
was purified by its specific amino-terminal tag (data not shown).
p80, p95, tTERT, and Telomerase RNA Interactions in Rabbit Reticu-
locyte Lysates. An important component of the telomerase com-
plex that was missing in these experiments is the telomerase
RNA. To test whether the telomerase RNA is needed for the
association of p80yp95 with tTERT, we used an in vitro tran-
scription and translation reaction in rabbit reticulocyte lysates to
express p80, p95, tTERT, and telomerase RNA. Because telom-
erase activity can be reconstituted in in vitro transcription and
translation lysates (25, 28, 29), we examined the association of
each component with active telomerase. The three protein
components were coexpressed in in vitro transcription and
translation lysates containing 35S-radiolabeled methionine. Te-
lomerase RNA was either coexpressed or added at the beginning
of the transcription and translation reaction. Immunoprecipita-
tions from these reactions were assayed for protein interactions,
telomerase RNA binding, and telomerase activity (Fig. 2).
Analysis of the in vitro transcription and translation reaction
before immunoprecipitation showed that all three proteins,
telomerase RNA, and telomerase activity were present. Preim-
mune serum did not immunoprecipitate p80, p95, tTERT,
telomerase RNA, or telomerase activity. Antibodies raised
against recombinant p80 and p95 coimmunoprecipitated the
p80yp95 protein complex but not tTERT or telomerase activity.
However, telomerase RNA did coimmunoprecipitate with the
p80yp95 complex. The tTERT antibody immunoprecipitated
tTERT, telomerase RNA, and telomerase activity but not the
p80yp95 complex. This suggested that p80 and p95 are not a part
of an active telomerase complex but are capable of interacting
with the telomerase RNA subunit as has been described (42).
Finally, we assayed telomerase activity in crude transcription and
translation lysates before immunoprecipitation. The presence of
p80 andyor p95 with tTERT and telomerase RNA affected
neither the telomerase activity level nor the length or pattern of
the products produced (data not shown).
To determine whether p80, p95, or both proteins were medi-
ating the interaction with telomerase RNA, each protein was
individually expressed in the in vitro transcription and translation
reaction. Results of immunoprecipitations showed that telom-
erase RNA was precipitated only in the reactions containing p80,
indicating that this is the subunit that associates with telomerase
RNA (data not shown). To address the specificity of telomerase
RNA binding, the amount of telomerase RNA added to in vitro
transcription and translation reactions was titrated to limiting
amounts. Telomerase RNA binding was assayed by immunopre-
cipitation followed by Northern analysis (Fig. 3A). At low levels
of input RNA, tTERT bound a significant amount of telomerase
RNA but the p80yp95 complex did not, suggesting that tTERT
has a higher specificity for telomerase RNA than p80. Autora-
diography showed equal amounts of p80, p95, and tTERT were
immunoprecipitated (Fig. 3B).
p80 and its human homologue TEP1 were previously shown to
bind telomerase RNA and vault RNA (45). To further test the
specificity of the p80 interaction with telomerase RNA, we
examined the interaction of p80 with several other unrelated
RNAs. Tetrahymena 7SL, U2, and a random RNA sequence were
included along with telomerase RNA in the in vitro transcription
and translation reaction, and immunoprecipitations were carried
out. All four RNAs were immunoprecipitated with antibodies
against p80; however, only the telomerase RNA was immuno-
precipitated with the antibodies against tTERT (Fig. 4 A and B).
Autoradiography showed that the appropriate proteins were
immunoprecipitated in these reactions (Fig. 4C). Thus, the
association of p80 with telomerase RNA could be due to its
nonspecific interaction with a variety of RNAs.
p80, p95, tTERT, and Telomerase in Vivo Interactions in Tetrahymena.
To investigate whether the interaction of p80 and p95 with
tTERT and telomerase RNA might require some additional
factor, we carried out immunoprecipitation experiments directly
from Tetrahymena extracts. Because of the low tTERT levels in
Tetrahymena, antibodies were first cross-linked to protein A
beads before immunoprecipitation (see Materials and Methods)
and then detected by Western analysis (Fig. 5A). A titration of
all three purified recombinant proteins probed by Western
analysis showed very similar signals for p80, p95, and tTERT,
indicating that the affinity of the antibodies is equivalent (data
not shown). In addition to Western analysis, the immunopre-
cipitation reactions were assayed for telomerase RNA and
telomerase activity (Fig. 5 B and C). Preimmune serum and a
control antibody against Tetrahymena histone protein (H1) did
not immunoprecipitate p80, p95, tTERT, or telomerase RNA,
and only background levels of telomerase activity were observed.
Fig. 2. Interactions of recombinant p80, p95, and tTERT and telomerase
RNA in rabbit reticulocyte lysates. p80, p95, tTERT, and telomerase RNA
were expressed by in vitro transcription and translation in the presence of
[35S]methionine by using rabbit reticulocyte lysates. The input material is
shown in lane 1. Immunoprecipitations were performed with the antibodies
indicated at the top of each lane (lanes 2–5). (A) Autoradiography of ex-
pressed and immunoprecipitated 35S-methionine-labeled proteins after
SDSyPAGE. PIS, preimmune serum. (B) Northern analysis to detect telom-
erase RNA from immunoprecipitations. (C) Telomerase enzyme activity
from immunoprecipitations.








Antibodies against p80 and p95 coimmunoprecipitated the
p80yp95 complex but not tTERT, telomerase RNA, or signifi-
cant levels of telomerase activity. The tTERT antibody immu-
noprecipitated tTERT, telomerase RNA, and high levels of
telomerase activity but not the p80yp95 complex. The tTERT
antibody also immunoprecipitated a tTERT degradation prod-
uct, which was also observed in baculovirus-infected insect cell
extracts and in in vitro transcription and translation lysates. As an
additional control, we preincubated the tTERT antibody with
the peptide against which the antibody was raised. This blocked
precipitation of tTERT, telomerase RNA, and telomerase ac-
tivity. This evidence suggested that the p80yp95 complex is not
associated with the bulk of the tTERTytelomerase RNA com-
plex in Tetrahymena cell extracts.
In the ciliate Euplotes crassus, telomerase activity fractionates
into several higher-order complexes during development (49).
To examine whether the p80yp95 complex is found associated
with telomerase at a particular developmental stage, we tested
the association of the components in both mated and vegetative
extracts. No association was detected in either type of extract
(data not shown). It remains possible that p80 and p95 are
associated with the telomerase core enzyme during a particular
stage in the Tetrahymena life cycle.
The complexes seen in Tetrahymena extracts were similar to
those observed in the in vitro transcription and translation
reactions except the p80yp95 complex did not interact with
telomerase RNA. Similarly, the p80yp95 complex did not inter-
act with Tetrahymena 7SL and U2 RNA in Tetrahymena extracts
(data not shown). Thus, the specificity of RNA–protein inter-
actions is significantly greater in vivo than in vitro. Perhaps p80
is in a specific cellular compartment andyor bound to a specific
RNA and is not free to exhibit nonspecific RNA interactions
in vivo.
Telomerase associated-proteins have a variety of functions
such as recruitment of telomerase to the telomere, RNA stabil-
ity, RNP assembly, and localization. In yeast, EST1, EST3, and
CDC13 are not required for telomerase enzyme activity but are
essential for telomere maintenance in vivo (32, 34). In ciliates,
the only other identified telomerase-associated protein is p43
from E. audiculatus (40). This protein shares homology to the
human La protein that has been implicated in several functions
such as RNA termination and RNP maturation of RNA poly-
merase III transcripts (reviewed in ref. 50). p43 likely associates
with telomerase because in ciliates telomerase RNA is a RNA
polymerase III transcript (51). Whether p80 and p95 play any
Fig. 3. Specificity of telomerase RNA protein binding. p80, p95, and tTERT
were expressed by in vitro transcription and translation in the presence of
[35S]methionine using rabbit reticulocyte lysates. After 1 h of protein synthe-
sis, telomerase RNA was added to a final concentration of 1.0, 0.25, or 0.05
ngyml and allowed to bind for 30 min. Immunoprecipitations were performed
with the p80-R (lanes 2–4), p95-R (lanes 5–7), and TERT-P (lanes 8–10) anti-
bodies from each reaction. (A) Northern analysis to detect telomerase RNA
from immunoprecipitations. A DNA loading control (L.C.) was added before
RNA extraction. (B) Autoradiography of immunoprecipitated 35S-methionine-
labeled proteins after SDSyPAGE (lanes 2–10). Input lysate after 1 h of protein
synthesis before telomerase RNA addition is shown in lane 1.
Fig. 4. Interactions of p80 with various RNAs. p80 and tTERT were expressed
individually by in vitro transcription and translation in the presence of [35S]me-
thionine using rabbit reticulocyte lysates. DNA templates for T7 transcription
of telomerase RNA, 7SL RNA, U2 RNA, and a random RNA derived from pUC19
were included in the reaction. Immunoprecipitations were performed with
the p80-R and TERT-P antibodies. (A) Northern analysis to detect telomerase
RNA, 7SL RNA, and random RNA from immunoprecipitations. (B) Northern
analysis to detect telomerase RNA and U2 RNA from immunoprecipitations.
(C) Autoradiography of immunoprecipitated 35S-methionine-labeled proteins
after SDSyPAGE.
Fig. 5. Interactions of p80, p95, tTERT, and telomerase RNA in Tetrahymena
extracts. Immunoprecipitations from Tetrahymena extracts were done with the
antibodies indicated at the top of each lane (lanes 1–5). PIS, preimmune serum.
The H1 antibody was raised against Tetrahymena linker histone protein H1.
Antibodies were cross-linked to protein A beads (see Materials and Methods).
The TERT-P antibody was also prebound with the carboxyl-terminal tTERT pep-
tide, against which it was raised before the addition to the extract (lane 6).
(A) Western analysis with antibodies against p80, p95, and tTERT of proteins
eluted from cross-linked antibody immunoprecipitation pellets. tTERT* indicates
a degradation product. (B) Northern analysis to detect telomerase RNA from
immunoprecipitations. Telomerase RNA* indicates a degradation product. (C)
Telomerase enzyme activity from immunoprecipitations.
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role in Tetrahymena telomerase is unclear. Tetrahymena strains
lacking p80 and p95 do not show any changes in telomerase
activity or in the levels of telomerase RNA. Loss of p95 affects
the resetting of telomere length during Tetrahymena develop-
ment; however, it is not clear whether this is a direct effect (43).
Mice that are deficient for the p80 homologue TEP1 also do not
show any changes in telomerase activity or telomere length (46).
Although TEP1 can associate with telomerase, it is predomi-
nantly found as a component of the abundant vault particles (45).
The affinity of p80 for RNA suggests that the Tetrahymena
p80yp95 complex may also be an RNP. The biochemical prop-
erties of this RNP may be similar to the TERTytelomerase RNA
complex and thus explain why the cellular p80yp95 complex
copurified with telomerase activity over a variety of columns
(41). Our current studies showing the lack of association of p80
and p95 with active telomerase both in vivo and in vitro suggest
that these proteins are not integral components of the telomer-
ase enzyme complex.
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